









Markets
/
Stocks
/
nasdaq-ptix
/

Protagenic Therapeutics Inc

PTIX

2.150USD

-0.100-4.44%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.97MMarket Cap

LossP/E TTM



Protagenic Therapeutics Inc

2.150

-0.100-4.44%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protagenic Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protagenic Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

237 / 407

Overall Ranking

477 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Protagenic Therapeutics Inc Highlights

StrengthsRisks

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Undervalued

The company’s latest PE is -9.29, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.75K shares, decreasing 30.91% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.98, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Protagenic Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.29, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -9.29, which is -100.00% below the recent high of 0.00 and -109.77% above the recent low of -19.48.

Score

Industry at a Glance

Previous score

6.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 237/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.88, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 3.25 and the support level at 1.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.31

Change

-0.43

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.169

Sell

RSI(14)

27.088

Sell

STOCH(KDJ)(9,3,3)

9.605

Oversold

ATR(14)

0.229

Low Volatility

CCI(14)

-145.039

Sell

Williams %R

95.122

Oversold

TRIX(12,20)

-1.242

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.404

Sell

MA10

2.679

Sell

MA20

2.954

Sell

MA50

3.326

Sell

MA100

3.324

Sell

MA200

3.705

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 4.55%, representing a quarter-over-quarter decrease of 70.44%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armen (Garo H.)

52.75K

Shaver (Pete)

27.89K

Virtu Americas LLC

18.81K

+374.23%

Armistice Capital LLC

17.14K

Alpine Global Management, LLC

16.35K

Morgan Stanley Smith Barney LLC

15.00K

Barrage (Khalil Z)

10.78K

Susquehanna International Group, LLP

10.16K

UBS Financial Services, Inc.

9.02K

Arrow (Alexander K)

3.27K

Risk Assessment

Currency: USD Updated: 2025-11-04

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.